Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Second primary malignancy
ADR ID BADD_A03952
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.16      Miscellaneous and site unspecified neoplasms malignant and unspecified
16.16.01      Neoplasms malignant site unspecified NEC
16.16.01.014      Second primary malignancy
Description Not Available
MedDRA Code 10039801
MeSH ID Not Available
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE)
Synonym
Second primary malignancy | Treatment related secondary malignancy
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00142Anastrozole0.000238%
BADD_D00193Axitinib0.002406%
BADD_D00194Azacitidine0.000280%
BADD_D00284Bortezomib0.000448%
BADD_D00286Bosutinib0.002239%
BADD_D00364Carboplatin0.000728%
BADD_D00414Ceritinib0.000112%
BADD_D00429Chlorambucil--
BADD_D00474Cisplatin0.000560%
BADD_D00535Crizotinib0.001343%
BADD_D00560Cytarabine0.001399%
BADD_D00566Dabrafenib0.000392%
BADD_D00567Dabrafenib mesylate--
BADD_D00594Deferasirox0.003717%
BADD_D00723Doxorubicin0.000951%
BADD_D00854Etoposide0.000280%
BADD_D00858Everolimus0.004051%
BADD_D00861Exemestane0.010979%
BADD_D00914Fludarabine0.000672%
BADD_D00931Fluorouracil0.000276%
BADD_D01110Hydroxyurea0.001063%
BADD_D01119Ibrutinib--
BADD_D01133Ifosfamide0.000168%
BADD_D01136Imatinib0.010353%
BADD_D01248Lapatinib0.000112%
BADD_D01253Lenalidomide--
BADD_D01257Letrozole0.004083%
BADD_D01366Medroxyprogesterone acetate0.000119%
BADD_D01480Mitoxantrone0.000112%
BADD_D01567Nilotinib0.010465%
The 1th Page    1 2    Next   Last    Total 2 Pages